News

Located in the Hangzhou Economic and Technology Area, the facility will package Merck medicines for China and the Asia Pacific region. Merck Manufacturing president and executive vice president

Insulin pens are medical plastic systems that enable diabetes sufferers to administer their regular insulin doses themselves in a pain-free procedure. Sanofi will perform the final assembly of

Various in vitro and in vivo studies validated a range of Anticalin targeted protein drug candidates designed to bind to a Daiichi’s target and thus an undisclosed payment

The trial is designed to assess the safety and efficacy profile of ixmyelocel-T administered via catheter-based injections against placebo. Aastrom Biosciences president and chief executive officer Nick Colangelo

The licensed technology leverages one of BioTime’s HyStem hydrogels for localized delivery of growth factors such as brain-derived neurotrophic factor to improve recovery from stroke. Several pre-clinical studies

Under the deal, SK Chemicals will carry out later-stage clinical phase 2 and 3 trials in Korea. The product is expected to be launched in 2018 in Korea

These patents represent the NCEs for the treatment of disorders associated with neurodegenerative diseases. The four product patents, two from China, one from Mexico and one from New

FEDI-2Rx range is used in pharmaceutical, biomedical and laboratory applications where installations require hot water sanitization to meet pharmacopoeia standards for purified water and water for injection. QUA

As per the agreement, CSL will leverage Xtend half-life extension technology in a program with known target. CSL will make an upfront payment in addition to preclinical, clinical,